Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3811 in Advanced Malignant Tumors
NCT05046847Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3811 in solid tumor, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose, Adverse Events and 1 more. Status: unknown.
02
Drugs
TQB3811
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05046847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046847.